New Jersey Assembly Bill A4520

New Jersey 2022-2023 Regular Session

• Introduced: 9/22/22
• Refer: 9/22/22

Caption

Prohibits excessive charges for drugs developed by publicly funded research.

Impact

A4520 seeks to impose a framework that aligns local drug pricing with more favorable international pricing standards, potentially making medications more affordable for New Jersey residents. This legislative measure may significantly affect the pharmaceutical market, particularly companies that rely on publicly funded research for developing their products. By establishing a benchmark, the law intends to mitigate excessive pricing practices that can occur from monopolistic control of drug patents and market power.

Summary

Bill A4520 is designed to regulate the pricing of drugs, biologics, and other healthcare technologies that have been developed, either partially or entirely, through research supported by federal or state government funding. Under this bill, it would be illegal for any entity to sell or advertise such drugs at prices higher than a benchmark set by international pricing norms. Specifically, the benchmark price would correspond to the lowest prices charged in comparable high-income countries, thereby potentially lowering drug costs within New Jersey when the products can be traced back to public funding.

Contention

While the intent of A4520 is to foster fairness and accessibility in drug pricing, it may face opposition from pharmaceutical companies arguing that such pricing limitations could stifle innovation and development of new drugs. Critics may voice concerns that the benchmark pricing could lead to reduced revenues for businesses invested in pharmacological advancements. Additionally, ensuring compliance with these pricing standards could lead to litigation and regulatory challenges, as companies adapt to the new pricing criteria being enforced.